WO2007044411A3 - Anti-myostatin antibodies - Google Patents
Anti-myostatin antibodies Download PDFInfo
- Publication number
- WO2007044411A3 WO2007044411A3 PCT/US2006/038818 US2006038818W WO2007044411A3 WO 2007044411 A3 WO2007044411 A3 WO 2007044411A3 US 2006038818 W US2006038818 W US 2006038818W WO 2007044411 A3 WO2007044411 A3 WO 2007044411A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- gdf
- epitope
- bind
- myostatin antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0616923-6A BRPI0616923A2 (en) | 2005-10-06 | 2006-10-05 | monoclonal antibodies, their uses and pharmaceutical composition |
CN2006800368248A CN101277976B (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
ES06816226.2T ES2533464T3 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
US12/066,664 US7635760B2 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
EA200801027A EA015589B1 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies and the use thereof |
JP2008534657A JP5052517B2 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibody |
EP06816226.2A EP1951756B1 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
KR1020087008254A KR101135220B1 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
CA002624976A CA2624976A1 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
AU2006302494A AU2006302494B2 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
IL189579A IL189579A0 (en) | 2005-10-06 | 2008-02-18 | Anti-myostatin antibodies |
NO20082073A NO20082073L (en) | 2005-10-06 | 2008-05-02 | Anti-myostatin antibodies |
US12/612,060 US7745583B2 (en) | 2005-10-06 | 2009-11-04 | Anti-myostatin antibodies |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72467005P | 2005-10-06 | 2005-10-06 | |
US60/724,670 | 2005-10-06 | ||
US72523505P | 2005-10-11 | 2005-10-11 | |
US60/725,235 | 2005-10-11 | ||
US72606205P | 2005-10-12 | 2005-10-12 | |
US60/726,062 | 2005-10-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/066,664 A-371-Of-International US7635760B2 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
US12/612,060 Continuation US7745583B2 (en) | 2005-10-06 | 2009-11-04 | Anti-myostatin antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007044411A2 WO2007044411A2 (en) | 2007-04-19 |
WO2007044411A3 true WO2007044411A3 (en) | 2007-08-16 |
Family
ID=37943347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/038818 WO2007044411A2 (en) | 2005-10-06 | 2006-10-05 | Anti-myostatin antibodies |
Country Status (13)
Country | Link |
---|---|
US (2) | US7635760B2 (en) |
EP (1) | EP1951756B1 (en) |
JP (1) | JP5052517B2 (en) |
KR (1) | KR101135220B1 (en) |
CN (1) | CN101277976B (en) |
AU (1) | AU2006302494B2 (en) |
BR (1) | BRPI0616923A2 (en) |
CA (1) | CA2624976A1 (en) |
EA (1) | EA015589B1 (en) |
ES (1) | ES2533464T3 (en) |
IL (1) | IL189579A0 (en) |
NO (1) | NO20082073L (en) |
WO (1) | WO2007044411A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2533464T3 (en) * | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
WO2007114319A1 (en) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
PL2066695T3 (en) * | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Anti-myostatin antibodies |
US11103497B2 (en) | 2007-06-01 | 2021-08-31 | Wyeth Llc | Treatment of imatinib resistant leukemia |
EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
KR100857861B1 (en) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Surface expression vector for fusion protein of myo-2 peptide multimer and myostatin, and microorganism transformed by therof |
PE20091163A1 (en) | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
SI2275443T1 (en) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
JO3340B1 (en) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
AR081556A1 (en) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | HUMANIZED ANTIGEN UNION PROTEINS |
MX2013001845A (en) * | 2010-08-16 | 2013-08-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods. |
AR082641A1 (en) | 2010-09-07 | 2012-12-19 | Imclone Llc | ANTI-VEGFR-3 ANTIBODY COMPOSITIONS |
TWI654204B (en) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | Antibody with calcium-dependent antigen binding ability |
CN102212545B (en) * | 2011-04-07 | 2013-05-08 | 北京济福霖生物技术有限公司 | Method for knocking out cattle beta-lactoglobulin gene by using zinc finger nucleases (ZFNs) |
CN102260711B (en) * | 2011-06-24 | 2013-09-18 | 北京济福霖生物技术有限公司 | Method for knocking out bovine myostatin gene by using zinc finger nuclease |
US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
CN102660577B (en) * | 2012-04-18 | 2013-12-25 | 山东省农业科学院奶牛研究中心 | Method for knocking out beta 6 subunit genes of bovine integrins by utilizing zinc finger nucleases (ZFNs) |
JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
NZ705370A (en) | 2012-08-24 | 2018-06-29 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
MY189682A (en) | 2012-09-13 | 2022-02-25 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
JPWO2014119634A1 (en) * | 2013-01-30 | 2017-01-26 | 国立研究開発法人国立精神・神経医療研究センター | Muscle increasing agent and pharmaceutical composition containing the same |
EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
HUE052232T2 (en) * | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
TW201920262A (en) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | Anti-activin A antibodies and uses thereof |
EP3119432B1 (en) | 2014-03-19 | 2020-01-08 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof |
EP2960653A1 (en) * | 2014-06-24 | 2015-12-30 | Stichting Kwaliteitsgarantie Vleeskalversector | Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
KR101860280B1 (en) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
KR20230155021A (en) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
ES2944357T3 (en) | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Treatment of metabolic diseases by inhibiting myostatin activation |
EP3593144A1 (en) * | 2017-03-10 | 2020-01-15 | UCL Business Ltd | Method relating to myostatin pathway inhibition |
CN111787981A (en) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | Method of altering body composition |
US20220220213A1 (en) | 2018-12-18 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138422A1 (en) * | 2001-09-26 | 2003-07-24 | Jane Aghajanian | Antibody inhibitors of GDF-8 and uses thereof |
WO2004037861A2 (en) * | 2002-10-22 | 2004-05-06 | Wyeth | Neutralizing antibodies against gdf-8 and uses therefor |
US20050014733A1 (en) * | 2003-06-02 | 2005-01-20 | Lisa-Anne Whittemore | Therapeutic and prophylactic methods for neuromuscular disorders |
WO2005094446A2 (en) * | 2004-03-23 | 2005-10-13 | Eli Lilly And Company | Anti-myostatin antibodies |
WO2006116269A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
WO2007024535A2 (en) * | 2005-08-19 | 2007-03-01 | Wyeth | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
WO2007047112A2 (en) * | 2005-10-12 | 2007-04-26 | Eli Lilly And Company | Anti-myostatin antibodies |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09507829A (en) * | 1993-03-19 | 1997-08-12 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | Growth differentiation factor-8 |
US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
CA2194660C (en) * | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
US6008434A (en) * | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
AU1276399A (en) | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
GB2333706A (en) | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
AU765214B2 (en) * | 1998-05-06 | 2003-09-11 | Metamorphix International, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
WO2000043781A2 (en) | 1999-01-21 | 2000-07-27 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
EP2192129A1 (en) * | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
EP2272864A3 (en) * | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
NZ529860A (en) * | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
JP2007535912A (en) * | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | Neutralizing epitope-based growth-enhancing vaccine |
US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
MX2007011400A (en) * | 2005-03-23 | 2007-10-11 | Wyeth Corp | Detection of gdf-8 modulating agents. |
WO2006128190A2 (en) * | 2005-05-27 | 2006-11-30 | The Regents Of The University Of California | Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists |
ES2533464T3 (en) * | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anti-myostatin antibodies |
MX2008007324A (en) * | 2005-12-06 | 2009-03-04 | Amgen Inc | Uses of myostatin antagonists. |
US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
PL2066695T3 (en) | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Anti-myostatin antibodies |
US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
-
2006
- 2006-10-05 ES ES06816226.2T patent/ES2533464T3/en active Active
- 2006-10-05 EP EP06816226.2A patent/EP1951756B1/en active Active
- 2006-10-05 JP JP2008534657A patent/JP5052517B2/en not_active Expired - Fee Related
- 2006-10-05 CN CN2006800368248A patent/CN101277976B/en not_active Expired - Fee Related
- 2006-10-05 KR KR1020087008254A patent/KR101135220B1/en not_active IP Right Cessation
- 2006-10-05 US US12/066,664 patent/US7635760B2/en not_active Expired - Fee Related
- 2006-10-05 AU AU2006302494A patent/AU2006302494B2/en not_active Ceased
- 2006-10-05 EA EA200801027A patent/EA015589B1/en not_active IP Right Cessation
- 2006-10-05 BR BRPI0616923-6A patent/BRPI0616923A2/en not_active IP Right Cessation
- 2006-10-05 CA CA002624976A patent/CA2624976A1/en not_active Abandoned
- 2006-10-05 WO PCT/US2006/038818 patent/WO2007044411A2/en active Application Filing
-
2008
- 2008-02-18 IL IL189579A patent/IL189579A0/en unknown
- 2008-05-02 NO NO20082073A patent/NO20082073L/en not_active Application Discontinuation
-
2009
- 2009-11-04 US US12/612,060 patent/US7745583B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138422A1 (en) * | 2001-09-26 | 2003-07-24 | Jane Aghajanian | Antibody inhibitors of GDF-8 and uses thereof |
WO2004037861A2 (en) * | 2002-10-22 | 2004-05-06 | Wyeth | Neutralizing antibodies against gdf-8 and uses therefor |
US20050014733A1 (en) * | 2003-06-02 | 2005-01-20 | Lisa-Anne Whittemore | Therapeutic and prophylactic methods for neuromuscular disorders |
WO2005094446A2 (en) * | 2004-03-23 | 2005-10-13 | Eli Lilly And Company | Anti-myostatin antibodies |
WO2006116269A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
WO2007024535A2 (en) * | 2005-08-19 | 2007-03-01 | Wyeth | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
WO2007047112A2 (en) * | 2005-10-12 | 2007-04-26 | Eli Lilly And Company | Anti-myostatin antibodies |
Also Published As
Publication number | Publication date |
---|---|
JP5052517B2 (en) | 2012-10-17 |
EP1951756A2 (en) | 2008-08-06 |
KR101135220B1 (en) | 2012-04-24 |
ES2533464T3 (en) | 2015-04-10 |
US20080299126A1 (en) | 2008-12-04 |
KR20080045733A (en) | 2008-05-23 |
NO20082073L (en) | 2008-06-17 |
US7745583B2 (en) | 2010-06-29 |
US20100087631A1 (en) | 2010-04-08 |
JP2009511480A (en) | 2009-03-19 |
CA2624976A1 (en) | 2007-04-19 |
IL189579A0 (en) | 2008-08-07 |
WO2007044411A2 (en) | 2007-04-19 |
AU2006302494B2 (en) | 2011-01-06 |
CN101277976A (en) | 2008-10-01 |
CN101277976B (en) | 2012-04-11 |
EP1951756B1 (en) | 2015-01-07 |
EA015589B1 (en) | 2011-10-31 |
US7635760B2 (en) | 2009-12-22 |
AU2006302494A1 (en) | 2007-04-19 |
BRPI0616923A2 (en) | 2011-07-05 |
EA200801027A1 (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007044411A3 (en) | Anti-myostatin antibodies | |
WO2005094446A3 (en) | Anti-myostatin antibodies | |
WO2007047112A3 (en) | Anti-myostatin antibodies | |
WO2008030706A3 (en) | Anti-myostatin antibodies | |
WO2016081746A8 (en) | Antibodies comprising modified heavy constant regions | |
WO2008115732A3 (en) | Anti-sclerostin antibodies | |
WO2006110214A3 (en) | Antibodies against mammalian metapneumovirus | |
MX2019013132A (en) | Antibodies comprising modified heavy constant regions. | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
WO2007113172A3 (en) | Antibodies against amyloid-beta peptide | |
WO2013106485A3 (en) | Ultralong complementarity determining regions and uses thereof | |
WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
HK1094167A1 (en) | Monoclonal antibodies to hepatocyte growth factor | |
JP2016094424A5 (en) | ||
WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
WO2005014653A3 (en) | Humanized chicken antibodies | |
RU2019100222A (en) | ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680036824.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 189579 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12066664 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008534657 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2624976 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/004565 Country of ref document: MX Ref document number: 2006302494 Country of ref document: AU Ref document number: 2809/DELNP/2008 Country of ref document: IN Ref document number: 1020087008254 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006816226 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006302494 Country of ref document: AU Date of ref document: 20061005 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801027 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: a200802966 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: PI0616923 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080404 |